Bank of New York Mellon
MIRM icon

Bank of New York Mellon’s Mirum Pharmaceuticals MIRM Stock Holding History

Bank of New York Mellon’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.4M Buy
669,974
+85,451
+15% +$8.58M 0.01% 799
2026
Q1 		$54M Buy
584,523
+18,944
+3% +$1.78M 0.01% 953
2025
Q4 		$44.7M Buy
565,579
+120,052
+27% +$8.62M 0.01% 1068
2025
Q3 		$32.7M Sell
445,527
-50,534
-10% -$3.21M 0.01% 1257
2025
Q2 		$25.2M Buy
496,061
+249,331
+101% +$11.1M ﹤0.01% 1396
2025
Q1 		$11.1M Buy
246,730
+122,402
+98% +$5.77M ﹤0.01% 1800
2024
Q4 		$5.14M Buy
124,328
+9,629
+8% +$401K ﹤0.01% 2277
2024
Q3 		$4.47M Sell
114,699
-28,301
-20% -$1.13M ﹤0.01% 2345
2024
Q2 		$4.89M Buy
143,000
+46,506
+48% +$1.22M ﹤0.01% 2356
2024
Q1 		$2.42M Sell
96,494
-20,790
-18% -$572K ﹤0.01% 2665
2023
Q4 		$3.46M Sell
117,284
-767
-0.6% -$23.2K ﹤0.01% 2555
2023
Q3 		$3.73M Buy
118,051
+5,861
+5% +$160K ﹤0.01% 2469
2023
Q2 		$2.9M Buy
112,190
+52,333
+87% +$1.39M ﹤0.01% 2628
2023
Q1 		$1.44M Sell
59,857
-5,655
-9% -$129K ﹤0.01% 2975
2022
Q4 		$1.28M Buy
65,512
+4,737
+8% +$93.6K ﹤0.01% 3078
2022
Q3 		$1.28M Sell
60,775
-12,872
-17% -$310K ﹤0.01% 3090
2022
Q2 		$1.43M Buy
73,647
+50,279
+215% +$1.19M ﹤0.01% 3019
2022
Q1 		$515K Sell
23,368
-826
-3% -$16.9K ﹤0.01% 3685
2021
Q4 		$385K Buy
24,194
+350
+1% +$5.45K ﹤0.01% 3953
2021
Q3 		$475K Buy
23,844
+416
+2% +$6.77K ﹤0.01% 3837
2021
Q2 		$405K Sell
23,428
-3,479
-13% -$62.3K ﹤0.01% 3863
2021
Q1 		$534K Sell
26,907
-663
-2% -$12.7K ﹤0.01% 3656
2020
Q4 		$481K Buy
27,570
+8,142
+42% +$160K ﹤0.01% 3633
2020
Q3 		$374K Sell
19,428
-575
-3% -$12.3K ﹤0.01% 3626
2020
Q2 		$389K Buy
20,003
+2,875
+17% +$48K ﹤0.01% 3593
2020
Q1 		$240K Buy
17,128
+5,620
+49% +$92.2K ﹤0.01% 3684
2019
Q4 		$282K Buy
+11,508
New +$123K ﹤0.01% 3827

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon's MIRM Position: Q2 2026 in Review

Bank of New York Mellon increased its Mirum Pharmaceuticals (MIRM) stake by 15% in Q2 2026, buying an estimated $8.58M and bringing the position to 669,974 shares worth $78.4M. The position accounts for 0.01% of the portfolio, ranked #799.

Bank of New York Mellon first reported a position in MIRM in Q4 2019 and has held it in 27 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Bank of New York Mellon held 669,974 shares of Mirum Pharmaceuticals worth $78.4M as of Q2 2026.
  • Bank of New York Mellon bought 85,451 Mirum Pharmaceuticals shares in Q2 2026, an estimated $8.58M.
  • Mirum Pharmaceuticals made up 0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #799 holding.
  • Bank of New York Mellon first reported a position in Mirum Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.